O	0	1	A
O	2	13	prospective
O	14	24	randomised
O	25	30	study
O	31	33	of
O	34	46	transvaginal
O	47	57	ultrasound
O	58	65	effects
O	66	68	of
B-intervention	69	78	tamoxifen
O	79	82	and
B-control	83	93	exemestane
O	94	96	in
B-eligibility	97	111	postmenopausal
I-eligibility	112	117	women
I-eligibility	118	122	with
I-eligibility	123	128	early
I-eligibility	129	135	breast
I-eligibility	136	142	cancer
O	142	143	.

O	144	145	A
O	146	155	reduction
O	156	158	of
O	159	173	gynaecological
O	174	181	adverse
O	182	188	events
O	189	192	has
O	193	197	been
O	198	206	reported
O	207	209	in
O	210	216	trials
O	217	226	comparing
O	227	236	aromatase
O	237	247	inhibitors
O	248	252	with
O	253	262	tamoxifen
O	263	265	as
O	266	274	adjuvant
O	275	284	treatment
O	285	287	in
O	288	302	postmenopausal
O	303	308	women
O	309	313	with
O	314	319	early
O	320	326	breast
O	327	333	cancer
O	333	334	,
O	335	338	but
O	339	344	there
O	345	347	is
O	348	349	a
O	350	357	paucity
O	358	360	of
O	361	371	randomised
O	372	379	studies
O	380	392	specifically
O	393	406	investigating
O	407	412	their
O	413	420	effects
O	421	423	on
O	424	427	the
O	428	434	uterus
O	434	435	.

O	436	438	We
O	439	445	report
O	446	450	here
O	451	454	the
O	455	462	results
O	463	465	of
O	466	467	a
O	468	479	prospective
O	480	485	phase
O	486	489	III
O	490	495	trial
O	496	505	comparing
O	506	509	the
O	510	517	effects
O	518	520	of
O	521	530	tamoxifen
O	531	534	and
O	535	545	exemestane
O	546	548	by
O	549	561	transvaginal
O	562	572	ultrasound
O	573	574	(
O	574	578	TVUS
O	578	579	)
O	579	580	.

B-eligibility	581	595	Postmenopausal
I-eligibility	596	604	patients
I-eligibility	605	609	with
I-eligibility	610	612	ER
I-eligibility	612	613	+
I-eligibility	614	619	early
I-eligibility	620	626	breast
I-eligibility	627	633	cancer
O	634	638	were
O	639	649	randomised
O	650	652	to
O	653	660	receive
O	661	670	tamoxifen
O	671	673	20
O	674	676	mg
O	677	681	once
O	682	687	daily
O	688	690	or
O	691	701	exemestane
O	702	704	25
O	705	707	mg
O	708	712	once
O	713	718	daily
O	719	721	as
O	722	730	adjuvant
O	731	738	hormone
O	739	746	therapy
O	746	747	.

O	748	752	TVUS
O	753	756	was
O	757	766	performed
O	767	769	at
O	770	778	baseline
O	779	782	and
O	783	785	at
O	786	787	6
O	788	791	and
O	792	794	12
O	795	801	months
O	802	804	to
O	805	812	measure
O	813	824	endometrial
O	825	834	thickness
O	835	836	(
O	836	838	ET
O	838	839	)
O	840	843	and
O	844	851	uterine
O	852	858	volume
O	859	860	(
O	860	862	UV
O	862	863	)
O	863	864	.

O	865	866	A
O	867	872	total
O	873	875	of
B-total-participants	876	879	123
O	880	885	women
O	886	890	were
O	891	901	randomised
O	902	904	to
O	905	914	tamoxifen
O	915	916	(
O	916	917	n
O	918	919	=
B-intervention-participants	920	922	61
O	922	923	)
O	924	926	or
O	927	937	exemestane
O	938	939	(
O	939	940	n
O	941	942	=
B-control-participants	943	945	62
O	945	946	)
O	946	947	.

O	948	949	A
O	950	963	significantly
O	964	970	higher
O	971	981	proportion
O	982	984	of
O	985	993	patients
O	994	996	in
O	997	1000	the
O	1001	1010	tamoxifen
O	1011	1016	group
O	1017	1020	had
O	1021	1030	increased
B-outcome	1031	1033	ET
I-outcome	1034	1036	at
I-outcome	1037	1038	6
I-outcome	1039	1042	and
I-outcome	1043	1045	12
I-outcome	1046	1052	months
O	1053	1057	from
O	1058	1071	randomisation
O	1072	1080	compared
O	1081	1085	with
O	1086	1089	the
O	1090	1100	exemestane
O	1101	1106	group
O	1107	1108	(
B-iv-bin-percent	1108	1110	66
I-iv-bin-percent	1110	1111	.
I-iv-bin-percent	1111	1112	1
I-iv-bin-percent	1112	1113	%
O	1114	1117	and
B-iv-bin-percent	1118	1120	64
I-iv-bin-percent	1120	1121	.
I-iv-bin-percent	1121	1122	3
I-iv-bin-percent	1122	1123	%
O	1124	1130	versus
B-cv-bin-percent	1131	1133	12
I-cv-bin-percent	1133	1134	.
I-cv-bin-percent	1134	1135	1
I-cv-bin-percent	1135	1136	%
O	1137	1140	and
B-cv-bin-percent	1141	1142	6
I-cv-bin-percent	1142	1143	.
I-cv-bin-percent	1143	1144	8
I-cv-bin-percent	1144	1145	%
O	1145	1146	,
O	1147	1159	respectively
O	1159	1160	;
O	1161	1162	P
O	1163	1164	<
O	1165	1166	0
O	1166	1167	.
O	1167	1171	0001
O	1171	1172	)
O	1172	1173	.

B-outcome	1174	1178	Mean
I-outcome	1179	1181	ET
I-outcome	1182	1185	and
I-outcome	1186	1188	UV
O	1189	1193	also
O	1194	1207	significantly
O	1208	1217	increased
O	1218	1222	with
O	1223	1232	tamoxifen
O	1233	1241	compared
O	1242	1244	to
O	1245	1255	exemestane
O	1256	1258	at
O	1259	1263	both
O	1264	1268	time
O	1269	1275	points
O	1276	1277	(
O	1277	1278	P
O	1279	1280	<
O	1281	1282	0
O	1282	1283	.
O	1283	1285	01
O	1286	1289	for
O	1290	1293	all
O	1294	1305	comparisons
O	1305	1306	)
O	1306	1307	.

O	1308	1317	Tamoxifen
O	1318	1320	is
O	1321	1331	associated
O	1332	1336	with
B-outcome	1337	1348	endometrial
I-outcome	1349	1359	thickening
O	1360	1363	and
O	1364	1373	increased
B-outcome	1374	1381	uterine
I-outcome	1382	1388	volume
O	1389	1391	in
O	1392	1393	a
O	1394	1405	significant
O	1406	1416	proportion
O	1417	1419	of
O	1420	1434	postmenopausal
O	1435	1440	women
O	1441	1445	with
O	1446	1451	early
O	1452	1458	breast
O	1459	1465	cancer
O	1465	1466	.

O	1467	1470	Our
O	1471	1476	study
O	1477	1485	confirms
O	1486	1489	the
O	1490	1494	lack
O	1495	1497	of
O	1498	1509	endometrial
O	1510	1517	effects
O	1518	1520	of
O	1521	1531	exemestane
O	1531	1532	,
O	1533	1538	which
O	1539	1542	may
O	1543	1545	be
O	1546	1548	of
O	1549	1557	interest
O	1558	1560	to
O	1561	1569	patients
O	1570	1573	and
O	1574	1584	clinicians
O	1585	1589	when
O	1590	1598	choosing
O	1599	1604	among
O	1605	1613	adjuvant
O	1614	1623	endocrine
O	1624	1631	options
O	1632	1635	for
O	1636	1642	breast
O	1643	1649	cancer
O	1649	1650	.
